Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of mycobacterium tuberculosis

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 127-134

  Sulochana, S ^a   Mitchison, D A ^b   Kubendiren, G ^c   Venkatesan, P ^c   Paramasivan, C N ^d  

^a SRI VENKATESWARA COLLEGE OF ENGINEERING   (India)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

Bactericidal activity; Moxifloxacin; Mycobacterium tuberculosis; Stationary culture

Indexed keywords

ISONIAZID; MOXIFLOXACIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG POTENTIATION; ENVIRONMENTAL EXPOSURE; GROWTH INHIBITION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; WILD TYPE;

EID: 67249088639     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.127     Document Type: Article

References (23)

1. Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuber Lung Dis 1998; 2: 265-271.
2. Hu Y, Coates ARM, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of My-cobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 653-657.
3. www.tballiance.org.
4. Nuermberger EL, Yoshimatsu T, Tyagi S, 'Brien RJO, Ver-non AN, Chaisson R E, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Res Crit Care Med 2004; 169: 421-426.
5. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher A. et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Res Crit Care Med 2006; 174: 331-338.
6. Conde MB, Efron A, Loredo C, Muzy-de-Souza G, Graca N, Cezar M., et al. A randomized, placebo-controlled trial of moxifloxacin vs. ethambutol in the initial phase of tuberculosis therapy in Brazil. Abstract 736-aLB. 471h Inter science Conference of Antimicrobial. Agents and Chemotherapy, Chicago, IL, 2007; September 19.
7. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuber Lung Dis 2008; 12:128-138.
8. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Res Crit Care Med 2004; 170:1131-1134.
9. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien, R.J, Vernon AN, Chaisson R E, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Res Crit Care Med 2004; 169: 421-426.
10. Kubendiran G, Paramasivan CN, Sulochana S, Mitchison DA. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 2006; 18: 617-623.
11. Herbert D, Paramasivan CN, Venkatesan P, Kubendiran G, Prabhakar R, Mitchison DA. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-2299.
12. Paramasivan CN, Sulochana S, Kubendiran G, Venkatesan P, Mitchison, DA. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 627-631.
13. Garton NJ, Waddell SJ, Sherrart AL, Lee SM, Smith RJ. Senner C, et al. Cytological and transcript analyses reveal fat an-dlLazy persister-like bacilli in tuberculous sputum. Plos Med. 2008; In press.
14. Park HD, Guinn KM, Harrell MI, Liao R, Voskui 1 MI, Tompa M, et al. Rv3133c/c(osR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microb 2003; 48, 833-843.
15. Stass H, Kubitza D, Halabi A, Delesen H. Pharmacokine-tics of moxifloxacin, a novel 8- methoxy - quinolone, in patients with renal dysfunction. Br J Clin Pharm. 2002; 53: 232-237.
16. Gosling RD, Ulso LO, Sam NE. Bongard E, Kanduma EG. Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Res Crit Care Med 2003; 168:1342-1345.
17. Pletz, M. Roux WRA. Roth de A. Neumann K-H. Mauch. H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-782.
18. Nuermberger E, Tyagi S, Tasneen R, Williams KN. Almeida D, Rosenthal I., et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis. Antimicrob Agents Chemother 2008; Feb 19: [Epub ahead of print].
19. Rosenthal I.M, Williams K, Tyagi S. Vernon AA, Peloquin CA, Bishai WR, et al. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Res Crit Care Med 2005; 172: 1457-1462.
20. Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Res Crit Care Med. 2006; 174: 94-101.
21. Rosenthal IM, Zhang M, Williams KN, Peloquin CA. Tyagi S, Vernon AA, et al Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4:e344.
22. Dorman S, Johnson J, Padayatchi N, Goldberg S. Boze-man L, Chaisson R Moxifloxacin vs. isoniazid in the first 2 months of treatment for pulmonary tuberculosis. Abstract L-736b. 47th Intersci. Conf. Antimicrobial Agents and Chemotherapy. Chicago, IL, 2007; September 19.
23. Carole DM, Sonya SS, Kwonjune JS, Michael LR, Sidney SA, et al. Comprehensive treatment extensively drug resistant tuberculosis. N Engl J Med; 359: 6, 563 - 564.